BE
Beta Drugs Ltd (BETA)
₹1,655.40
Mkt cap
₹1,993 Cr
P/E ratio
38.40
P/B
4.20
Div yield
0.00%
ROE
18.80%
ROCE
19.20%
EPS (TTM)
₹43.11
Book value
₹394
52W range
990–2,808
Sector
Healthcare
Price history
Previous close
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets. [1]
NSE BETA
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−41.04% from high₹1,655
₹990+67.20% from low₹2,808
Current
₹1,655.40
Prev close
₹1,764.20
Day
−6.17%
Price performance
1D
−6.18%
1W
−8.93%
1M
−16.03%
3M
−27.88%
6M
+33.79%
1Y
−0.66%
YTD
+1.60%
Financials
Revenue, profit & margin
P/E ratio
38.4×
BETA is 15% above the sector median of 33.4×
BETA38.4×
Sector median33.4×
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 88 | 94 | 100 | 103 | 87 | 94 | 126 | 137 | |
| YoY Sales growth | -1% | +0% | +25% | +33% | |||||
| Expenses | 70 | 76 | 81 | 82 | 70 | 76 | 98 | 107 | |
| Operating Profit | 18 | 17 | 20 | 21 | 17 | 18 | 27 | 30 | |
| OPM % | 21% | 18% | 20% | 21% | 19% | 19% | 22% | 22% | |
| Other Income | -1 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | |
| Interest | 2 | 3 | 3 | 4 | 4 | 4 | 3 | 2 | |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | |
| Profit before tax | 12 | 12 | 16 | 16 | 10 | 12 | 22 | 26 | |
| Tax % | 25% | 26% | 25% | 26% | 19% | 24% | 25% | 25% | |
| Net Profit | 9 | 9 | 12 | 12 | 9 | 9 | 16 | 19 | |
| EPS in Rs | 8.86 | 8.95 | 11.59 | 12.11 | 8.40 | 8.93 | 14.25 | 16.68 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −3.88% · closed higher next day 1 of last 1
| Q2FY27 | |
|---|---|
| Broadcast | 22 Oct '26 |
| Earnings day | −3.88% |
| +1 day | +0.35% |
| +5 days | −8.76% |
| +15 days | −7.85% |
| +30 days | — |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202658.91%Promoter
Promoters58.91%0.19
FIIs1.37%0.35
DIIs6.45%0.22
Public33.27%0.38
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,870.00 | 36.46 | 4,48,676 | 0.86% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,150.00 | 86.62 | 2,95,997 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,668.80 | 81.80 | 1,77,586 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,338.00 | 94.28 | 1,26,325 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,204.20 | 26.51 | 1,20,119 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,388.00 | 41.41 | 1,15,936 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,388.00 | 36.11 | 1,12,135 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Beta Drugs Ltd | ₹1,792.50 | 38.40 | 1,993 | 0.00% | 19 | +51.80% | 137 | +32.98% | 19.16% |
| Median: 160 Co. | ₹445.73 | 33.35 | 2,016 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports9
Concall transcripts29
TranscriptOct 2026PPTOct 2026RECOct 2026PPTJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptNov 2024PPTNov 2024TranscriptMay 2024PPTMay 2024TranscriptNov 2023PPTNov 2023TranscriptMay 2023PPTMay 2023TranscriptNov 2022PPTNov 2022TranscriptMay 2022
Credit ratings6
Announcements5
Board Meeting - Intimation 16 Nov - BETA DRUGS LIMITED has informed about Board Meeting to be held on 19-Nov-2026 to consider Other business.Trading Window 16 Nov - Trading window closed16 Nov 2026 to 21 Nov 2026 ahead of board meeting.Board Meeting - Other business matters 16 Nov - Board meeting on 19 Nov 2026 to discuss strategic initiatives; trading window closes16 Nov to 21 Nov.Monitoring Agency Report 12 Nov - Brickwork report for quarter ended September 30, 2026 shows no deviation in Rs 117.01 crore preferential issue proceeds.Updates 2 Nov - Board approved Q2/H1 FY27 results on 22 Oct 2026; H1 consolidated revenue rose 29.2% to Rs 263.04 Cr.






